Klotho Neurosciences, Inc. (KLTO)
- Previous Close
2.0100 - Open
1.7600 - Bid 1.3500 x 100
- Ask 2.0000 x 100
- Day's Range
1.3000 - 1.7600 - 52 Week Range
0.1140 - 6.8300 - Volume
45,304,241 - Avg. Volume
34,437,319 - Market Cap (intraday)
47.117M - Beta (5Y Monthly) 0.14
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates comprise KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.
klothoneuro.comRecent News: KLTO
View MorePerformance Overview: KLTO
Trailing total returns as of 6/11/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KLTO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KLTO
View MoreValuation Measures
Market Cap
65.31M
Enterprise Value
66.52M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
92.59
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-151.41%
Return on Equity (ttm)
-1,544.44%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-7.71M
Diluted EPS (ttm)
-0.3000
Balance Sheet and Cash Flow
Total Cash (mrq)
565.87k
Total Debt/Equity (mrq)
276.80%
Levered Free Cash Flow (ttm)
-1.95M